Nevro (NYSE:NVRO) released its quarterly earnings results on Thursday. The medical equipment provider reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.01), Briefing.com reports. The business had revenue of $97.96 million for the quarter, compared to the consensus estimate of $96.87 million. Nevro had a negative net margin of 14.09% and a negative return on equity of 17.27%. The firm’s revenue for the quarter was up 38.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.34) EPS.
Nevro (NVRO) traded down $2.70 during trading hours on Thursday, reaching $79.65. 340,376 shares of the company were exchanged, compared to its average volume of 360,047. Nevro has a 1-year low of $65.00 and a 1-year high of $99.63. The company has a quick ratio of 6.81, a current ratio of 8.78 and a debt-to-equity ratio of 0.59. The firm has a market cap of $2,360.00, a price-to-earnings ratio of -54.93 and a beta of -0.59.
A number of research firms have recently weighed in on NVRO. Canaccord Genuity cut their price target on shares of Nevro from $120.00 to $110.00 and set a “buy” rating on the stock in a report on Tuesday, November 7th. BidaskClub downgraded shares of Nevro from a “hold” rating to a “sell” rating in a report on Saturday, October 28th. Leerink Swann reiterated an “outperform” rating and issued a $110.00 target price (up from $105.00) on shares of Nevro in a research note on Tuesday, November 7th. Northland Securities reiterated a “buy” rating and issued a $96.00 target price on shares of Nevro in a research note on Tuesday, November 7th. Finally, TheStreet upgraded shares of Nevro from a “d+” rating to a “c-” rating in a research note on Monday, November 6th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $99.25.
TRADEMARK VIOLATION WARNING: “Nevro (NVRO) Releases Earnings Results, Misses Estimates By $0.01 EPS” was first posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another website, it was illegally stolen and reposted in violation of US and international copyright & trademark laws. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/02/23/nevro-nvro-releases-earnings-results-misses-estimates-by-0-01-eps.html.
Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain.
Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.